Tocilizumab for the treatment of steroid refractory graft-versus-host disease

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 12, 2011, Pages 1862-1868

  Drobyski, William R ^a   Pasquini, Marcelo ^a   Kovatovic, Kathy ^a   Palmer, Jeanne ^a   Douglas Rizzo, J ^a   Saad, Ayman ^a   Saber, Wael ^a   Hari, Parameswaran ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Graft versus host disease; Interleukin 6; Steroid refractory; Tocilizumab

Indexed keywords

ALEMTUZUMAB; BUDESONIDE; HYDROCORTISONE; HYDROXYCHLOROQUINE; IMATINIB; INFLIXIMAB; LIDOCAINE; METHOTREXATE; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCTREOTIDE; PREDNISONE; RAPAMYCIN; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; TOCILIZUMAB;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLERGY; ALLOGENEIC STEM CELL TRANSPLANTATION; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; HYPERBILIRUBINEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; MALE; OFF LABEL DRUG USE; SCLERODERMA; SIDE EFFECT; TREATMENT RESPONSE;

ADRENAL CORTEX HORMONES; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; COHORT STUDIES; DRUG RESISTANCE; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED;

EID: 81255163590     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.07.001     Document Type: Article

References (39)

1. Weisdorf D., Haake R., Blazar B., et al. Treatment of moderate/severe acute graft versus host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 1990, 75:1024-1030.
2. Macmillan M.L., Weisdorf D.J., Wagner J.E., et al. Response of 443 patients to steroids as primary therapy for acute graft versus host disease: comparison of grading systems. Biol Blood Marrow Transplant 2002, 8:387-394.
3. Basara N., Blau W.I., Romer E., et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients. Bone Marrow Transplant 1998, 22:61-65.
4. Kim J.G., Sohn S.K., Kim D.H., et al. Different efficacy of mycophenolate mofetil as salvage treatment fro acute and chronic GVHD after allogeneic stem cell transplant. Eur J Haematol 2004, 73:56-61.
5. Bolanos-Meade J., Jacobsohn D.A., Margolis J., et al. Pentostatin in steroid-refractory acute graft versus host disease. J Clin Oncol 2005, 23:2661-2668.
6. Benito A.I., Furlong T., Martin P.J., et al. Sirolimus (Rapamycin) for the treatment of steroid-refractory acute graft versus host disease. Transplantation 2001, 72:1924-1929.
7. Hoda D., Pidala J., Salgado-Vila N., et al. Sirolimus for treatment of steroid-refractory acute graft versus host disease. Bone Marrow Transplant 2010, 45:1347-1351.
8. Vogelsang G.B., Hess A.D., Santos G.W. Thalidomide for treatment of graft versus host disease. Bone Marrow Transplant 1988, 3:393-398.
9. Greinix H.T., Volc-Platzer B., Kalhs P., et al. Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft versus host disease: a pilot study. Blood 2000, 96:2426-2431.
10. Couriel D., Saliba R., Hicks K., et al. Tumor necrosis alpha blockade for the treatment of acute GVHD. Blood 2004, 104:649-654.
11. Ho V.T., Zahrieh D., Hochberg E., et al. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft versus host disease after allogeneic hematopoietic stem cell transplantation. Blood 2004, 104:1224-1226.
12. Shaughnessy P.J., Bachier C., Grimley M., et al. Denileukin difitox for the treatment of steroid-resistant acute graft versus host disease. Biol Blood Marrow Transplant 2005, 11:188-193.
13. Cutler C., Miklos D., Kim H.T., et al. Rituximab for steroid-refractory chronic graft versus host disease. Blood 2006, 108:756-762.
14. Schub N., Gunther A., Schrauder A., et al. Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effective. Bone Marrow Transplant 2011, 46:143-147.
15. Hill G.R., Crawford J.M., Cooke K.R., Brinson Y.S., Pan L., Ferrara J.L. Total body irradiation and acute graft versus host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 1997, 90:3204-3213.
16. Ferrara J.L., Levine J.E., Reddy P., Holler E. Graft versus host disease. Lancet 2009, 373:1550-1561.
17. Imamura M., Hashino S., Kobayashi H., et al. Serum cytokine levels in bone marrow transplantation: synergistic interaction of interleukin 6, interferon gamma, and tumor necrosis factor alpha in graft versus host disease. Bone Marrow Transplant 1994, 13:745-751.
18. Cavet J., Dickinson A.M., Norden J., Taylor P.R.A., Jackson G.H., Middleton P.G. Interferon γ and interleukin 6 gene polymorphisms associate with graft versus host disease in HLA-matched sibling bone marrow transplantation. Blood 2001, 98:1594-1600.
19. Socie G., Loiseau P., Tamouza R., et al. Both genetic and clinical factors predict the development of graft versus host disease after allogeneic hematopoietic stem cell transplantation. Transplantation 2001, 72:699-706.
20. Chen X., Das R., Komorowski R., Beres A., Hessner M.J., Mihara M., Drobyski W.R. Blockade of interleukin 6 signaling augments regulatory T cell reconstitution and attenuates the severity of graft versus host disease. Blood 2009, 114:891-900.
21. Tawara I., Koyama M., Liu C., et al. Interleukin 6 modulates graft versus host disease after experimental allogeneic bone marrow transplantation. Clin Cancer Res 2011, 17:77-88.
22. Nishimoto N., Yoshizaki K., Miyasaka N., et al. Treatment of rheumatoid arthritis with humanized anti-interleukin 6 receptor antibody. Arthritis Rheum 2004, 50:1761-1769.
23. Yokota S., Imagawa T., Mori M., et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008, 371:998-1006.
24. Matsuyama M., Suzuki T., Tsuboi H., et al. Anti-interleukin 6 receptor antibody (Tocilizumab) treatment of multicentric Castleman's disease. Intern Med 2007, 46:771-774.
25. Gergis U., Arnason J., Yantiss R., Shore T., Wissa U., Feldman E. Effectiveness and safety of tocilizumab, an anti-interleukin 6 receptor monoclonal antibody in a patient with refractory GI graft versus host disease. J Clin Oncol 2010, 28:e602-e604.
26. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA matched sibling donors. Transplantation 1974, 18:295-304.
27. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft versus host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
28. Pavletic S.Z., Martin P., Lee S.J., et al. Measuring therapeutic response in chronic graft versus host disease: National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft versus host disease: IV. Response criteria working group report. Biol Blood Marrow Transplant 2006, 12:252-266.
29. Das R., Chen X., Komorowski R., Hessner M.J., Drobyski W.R. Interleukin 23 secretion by donor antigen presenting cells is critical for organ-specific pathology in graft versus host disease. Blood 2009, 113:2352-2362.
30. Hill G.R., Olver S.D., Kuns R.D., et al. Stem cell mobilization with G-CSF induces type 17 differentiation and promotes scleroderma. Blood 2010, 116:819-828.
31. H17 and regulatory T cells. Nature 2006, 441:235-238.
32. Veldhoen M., Hocking R.J., Atkins C.J., Locksley R.M., Stockinger B. TGF beta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17 producing T cells. Immunity 2006, 24:179-186.
33. Roll P., Muhammad K., Schumann M., Kleinert S., Einsele H., Dorner T., Tony H.O. In vivo effect of the anti-interleukin 6 receptor inhibitor tocilizumab on the B cell compartment. Arthritis Rheum 2011 May, 63(5):1255-1264.
34. Kawaguchi Y., Hara M., Wright T.M. Endogenous IL-1 alpha from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. J Clin Invest 1999, 103:1253-1260.
35. Shima Y., Kuwahara Y., Murota H., et al. The skin of patients with systemic sclerosis softened during treatment with anti-IL receptor antibody tocilizumab. Rheumatology 2010, 49:2408-2412.
36. Nishimoto N., Miyasaka N., Yamamoto K., Kawai S., Takeuchi T., Azuma J. Long term safety and efficacy of tocilizumab, an anit-IL-6-receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5 year extension study. Ann Rheum Dis 2009, 68:1580-1584.
37. Campbell L., Chen C., Bhagat S.S., Parker R.A., Ostor A.J.K. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab; a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology 2011, 50:552-562.
38. Rand K.H., Gibbs K., Derendorf H., Graham-Pole J. Pharmacokinetics of intravenous immunoglobulin (Gammagard) in bone marrow transplant patients. J Clin Pharmacol 1991, 31:1151-1154.
39. Ito H., Takazoe M., Fukuda Y., et al. A pilot randomized trial of a human anti-IL-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004, 126:989-996.